SUBJ: Resilence necessary for healthy life
SUBtitle: Current lifespan 120 to 150 years
SHORT NOTES: Loss of resilience turned out to be related to chronic diseases and elevated all-cause mortality risks; “135” is the most likely value for the maximum human lifespan in perfect conditions; The National Institute on Aging has awarded a $5 million grant to conduct a first-in-human Phase 1 clinical trial of a gene therapy for treating Alzheimer’s disease (AD) or Mild Cognitive Impairment (MCI); DEMENTIA Enlightened?! A Systematic Literature Review of the Influence of Indoor Environmental Light on the Health of Older Persons with Dementia.
LONG NOTES
Healthy human subjects turned out to be very resilient, whereas the loss of resilience turned out to be related to chronic diseases and elevated all-cause mortality risks. The rate of recovery to the equilibrium baseline level after stresses was found to deteriorate with age. Accordingly, the time needed to recover was getting longer and longer. Being around 2 weeks for 40 y.o. healthy adults the recovery time stretched to 6 weeks for 80 y.o. on average in the population. (Roc note: The easiest way to retain resilience is to take SAMe. This is the natural substance kids make a ton of but adults do not, which regulates adrenaline, allowing control of happy and sad moods. I take 200 mg every morning.)
The substance of this report actually supports the idea that there is a basal “background metabolic aging rate” and that no amount of optimal conditions, curing cancer, or avoiding accidents will prevent death by age 135, plus or minus 15. This actually fits strongly into the “centrist” maximum lifespan camp, neither overskeptical nor overoptimistic. Yet the headlines tend to veer toward “Live to 150!”. No, that is NOT what is being said here. First of all, the range of “120-150” means that “135” is the most likely value for the maximum human lifespan…in perfect conditions where all lifespan-shortening variables are removed from the equation.
The National Institute on Aging (NIA), part of the National Institutes
of Health, has awarded a $5 million grant to researchers at University
of California San Diego School of Medicine to conduct a first-in-human
Phase 1 clinical trial of a gene therapy for treating Alzheimer’s
disease (AD) or Mild Cognitive Impairment (MCI), a condition that often
precedes full-blown dementia.
DEMENTIA Enlightened?! A Systematic Literature Review of the Influence of Indoor Environmental Light on the Health of Older Persons with Dementia in Long-Term Care Facilities
